



Received on 05 April, 2018; received in revised form, 10 June, 2018; accepted, 18 June, 2018; published 01 December, 2018

## NEWBOULDIA LAEVIS LEAF FACILITATES INSULIN SECRETION, GLUCOSE UPTAKE AND PANCREATIC FUNCTION IN ALLOXAN-INDUCED HYPERGLYCAEMIA IN WISTAR RATS

Ugochukwu Vincent Igbokwe<sup>1</sup>, Ejike Daniel Eze<sup>\*2</sup>, Moses Dele Adams<sup>3</sup>, Denen Atsukwei<sup>4</sup> and Mazi Ikechukwu<sup>1</sup>

Department of Physiology<sup>1</sup>, Faculty of Basic Medical Sciences, College of Health Sciences, Nnamdi Azikiwe University, Nnewi Campus, Anambra State, Nigeria.

Department of Physiology<sup>2</sup>, Faculty of Biomedical Sciences, Kampala International University, Western Campus, Ishaka, Bushenyi, Uganda.

Department of Biochemistry<sup>3</sup>, Faculty of Science and Technology, Bingham University, Karu, Nigeria.

Department of Radiology<sup>4</sup>, Federal Medical Centre, Keffi, Nasarawa State, Nigeria.

### Keywords:

*Newbouldia laevis*,  
Bignoniaceae, Pancreatic  
Function, Antihyperglycaemia,  
Hyperglycaemia, Glucose utilization

### Correspondence to Author:

**Ejike Daniel Eze**

Ph.D, Senior Lecturer,  
Department of Physiology,  
Faculty of Biomedical Sciences,  
Kampala International University,  
Western Campus, Ishaka, Bushenyi,  
Uganda.

**E-mail:** daniel.ejike@kiu.ac.ug

**ABSTRACT:** The antihyperglycaemic activity of aqueous leaf extract of *Newbouldia laevis* (ALENL) was evaluated in rats. Twenty-five rats of both sexes (120 - 160 g) were divided into five groups (A-E) of 5 animals each. Group A (control) rats were administered 0.5 ml of distilled water (DW) orally while those in group B received 100 mg/kg body weight of ALENL. Animals in groups C, D and E which were induced into hyperglycaemia (intraperitoneal administration of 150 mg/kg body weight of alloxan) were also administered DW, 100 and 200 mg/kg body weight of ALENL respectively, once daily for 14 days. Blood glucose levels (BGL) were determined at interval of two days. Alloxan significantly ( $p < 0.05$ ) increased BGL in the DW treated hyperglycaemic animals (DWTGA) from  $48.00 \pm 1.79$  to  $142.80 \pm 2.35$  mg/dl after 24 h. After 2 days, administration of the extract at 100 and 200 mg/kg body weight increased blood glucose level but this increase was not statistically significant ( $p > 0.05$ ) when compared with the DWTGA. On day 4, the extract at both doses decreased blood glucose level but this decrease was not statistically significant ( $p > 0.05$ ) when compared with the DWTGA. On days 6, 8, 10, 12 and 14, the extract at both doses decreased blood glucose level but this decrease was statistically significant ( $p < 0.05$ ) when compared with the DWTGA. The study indicates that the extract at both doses possess antihyperglycaemic properties which may have acted by stimulating glucose utilization by peripheral tissues or increasing insulin production by the pancreas from regenerated  $\beta$ -cells.

**INTRODUCTION:** Hyperglycaemia or high blood sugar is a metabolic condition in which an excessive amount of glucose circulates in the blood plasma<sup>1</sup>.

Acute hyperglycemia involves glucose levels that are extremely high and most often seen in persons who have uncontrolled insulin-dependent diabetes<sup>2</sup>. In untreated hyperglycemia, a condition called ketoacidosis may develop because decreased insulin levels increase the activity of hormone sensitive lipase, thus affecting the heart, and may result in chronic hyperglycemia<sup>3, 4</sup>. Symptoms associated with acute or chronic hyperglycemia include polyphagia, polydipsia, polyuria, weight loss, fatigue, blurred vision, poor wound healing,

<p><b>QUICK RESPONSE CODE</b></p> 	<p><b>DOI:</b> 10.13040/IJPSR.0975-8232.9(12).5079-85</p> <hr/> <p>Article can be accessed online on: www.ijpsr.com</p> <hr/> <p>DOI link: <a href="http://dx.doi.org/10.13040/IJPSR.0975-8232.9(12).5079-85">http://dx.doi.org/10.13040/IJPSR.0975-8232.9(12).5079-85</a></p>
---	--

feet tingling, erectile dysfunction, external ear infection, cardiac arrhythmia, stupor, coma, seizures etc. Causes of hyperglycaemia are diabetes mellitus, drugs<sup>5</sup>, critical illness and oxidative stress<sup>6</sup>.

Hyperglycaemia-induced oxidative and nitrosative stress has also been singled out as one of the major links between diabetes and diabetic complications<sup>6</sup>.<sup>7</sup> Hyperglycaemia leads to generation of free radicals due to autooxidation of glucose and glycosylation of proteins. The persistent increase in reactive oxygen species (ROS) and reactive nitrogen species (RNS) accompanied by a decrease in antioxidant activity lead to the occurrence of oxidative and nitrosative stress which can cause endothelial dysfunction, insulin resistance as well as alterations in number and functions of pancreatic  $\beta$ -cells which may eventually result in diabetic microvascular and macrovascular complications<sup>8</sup>. Diabetes mellitus is therefore a group of metabolic diseases characterized by hyperglycemia, resulting from defects in insulin secretion, insulin action, or both. Report have it that protection against the alloxan-induced hyperglycaemia can be achieved by a combination of superoxide dismutase and catalase, which completely prevents redox imbalance between alloxan, ROS species generation and antioxidant status<sup>9, 10</sup>. Studies have also been reported in the open scientific literature on induced hyperglycaemia following administration of alloxan and or extracts of medicinal plants<sup>5, 11, 12, 13, 14</sup>. This has therefore necessitated more researches on the effects of medicinal plants on alloxan-induced hyperglycaemia in animals.

Medicinal plants are sources of direct therapeutic agents or new raw material base for the synthesis of useful antihyperglycaemic drug<sup>15, 16</sup>. The use of plants in traditional medicine referred to as herbalism or simply botanical medicine falls outside the mainstream of the western or orthodox medicine<sup>17, 18</sup>. Plants contain active components (secondary metabolites) which possess medical properties that are harnessed for the treatment of different diseases<sup>19</sup>. Worldwide, more than 171 million people suffer from diabetes, making it one of the most common non-communicable diseases and the number of affected individuals with diabetes is expected to double by 2025<sup>20</sup>.

The countries with the largest number of diabetics are India, China, and United states<sup>21</sup>. In the past decades, research has been focused on scientific evaluation of traditional drugs of plant origin, and screening of more effective and safe anti-hyperglycaemic agents has continued to be a quarrying domain<sup>22, 23</sup>. A very large area of Nigeria ecological zones is populated with many plant species which have found their usefulness either directly or indirectly for humans<sup>24</sup>. The medicinal values of many of these plants cannot be over emphasized in the light of oral traditions and folklores from the distant past that have continued to extol the healing virtues of these plants and their extracts. This has therefore prompted more studies on the possible effects of medicinal plants on alloxan-induced hyperglycaemia in animals. One plant of interest is *Newbouldia leavis*.

*Newbouldia leavis* (Bignoniaceae) is commonly known as African Border tree or boundary tree in English<sup>25</sup>. It is called "Aduruku" in Hausa; "Ogirisii" in Igbo; "Ikhimi" in Edo and "Akoko" in Yoruba language<sup>26</sup>. It grows to a height of about 7.8 (up to 15 metres), more usually a shrub of 2 - 3 metres, with many stemmed forming clumps of gnarled branches. It is easily recognized by its short branches, coarsely toothed leaflets as well as purple and white flowers<sup>27</sup>. *Newbouldia leavis* is native to tropical Africa and grows from Guinea Savannas to dense forests, or moist and well-drained soils<sup>28</sup>. One remarkable thing about this plant is that it hardly dies hence it is used to indicate boundary marks among the Igbo people of South Eastern Nigeria<sup>29</sup>. Previous reports have shown that *N. laevis* leaves possess sedative<sup>30</sup>, antidiabetic<sup>31</sup> haematological<sup>32</sup>, erythrocyte stability / membrane protection<sup>33</sup>, fertility<sup>34</sup>, and antioxidant<sup>35</sup> activities.

Although, the aqueous leaf extract of *N. laevis* have been reportedly evaluated by Omonkhelin *et al.*, and Owolabi *et al.*, for its antihyperglycaemic activity at 100, 200 and 400 mg/kg body weight<sup>31, 36</sup> as well as Ajah *et al.*, and Osigwe *et al.*, at 200 and 250, 500, 1000 mg/kg body weight<sup>37, 38</sup> respectively in alloxan-induced hyperglycaemic rats, there is dearth of information in the open scientific literature on the possibility of antidiabetic activity of *N. laevis* leaf on alloxan-induced hyperglycaemia especially at the specific pharma-

cologic dose of 100 and 200 mg/kg body weight. Therefore, the present study was undertaken to provide information on the anti-hyperglycaemic effects of aqueous leaf extract of *N. laevis* on alloxan-induced hyperglycaemia in rats.

## MATERIALS AND METHODS:

### Materials:

#### Collection of Plant Materials and Authentication:

Fresh leaves of *Newbouldia laevis* were gotten from a farm at Okofia in Nnewi and authenticated by a botanist in the Department of Plant Biology, Nnamdi Azikiwe University, Akwa, Anambra State, Nigeria while the botanical authentication of the plant was confirmed at the Forestry Research Institute of Nigeria (FRIN) Ibadan, Nigeria where a voucher specimen (no. FHI 107753) was deposited for future reference.

**Experimental Animals:** Albino rats (*Rattus norvegicus*) of both sexes weighing 120 - 160 g were obtained from the animal house of the Department of Human Physiology, Nnamdi Azikiwe University, College of Health Sciences, Nnewi Campus, Nigeria. The animals which were housed in aluminium cages placed in well ventilated standard housing conditions (temperature: 28-31 °C; photoperiod: 12 h; humidity: 50 - 55%) were allowed free access to rat pellets (Bendel Feeds and Flour Mills Ltd., Ewu, Nigeria) and tap water.

**Glucose Meter and Test Strips:** Accu-Chek® active compact plus glucometer and Accu-Chek® active test strips were products of Roche Diagnostics, Mannheim, Germany.

### Methods:

**Ethical Clearance:** All the animal experiments were carried out in accordance with the guidelines of the Nnamdi Azikiwe University, Faculty of Basic Medical Sciences, Nnewi Campus Animal Ethical Committee Approval on the use of laboratory animals.

**Preparation of Aqueous Leaf Extract of *Newbouldia laevis*:** Dried leaves of *Newbouldia laevis* were pulverized using electric blender (Kenwood, Model BL335, Taiwan, China). A known weight (200 g) of the powder was extracted in 2 litre of distilled water for 48 h at room temperature. The mixture was filtered with

Whatman no. 1 filter paper (Maidstone, UK). The resulting filtrate was concentrated on steam bath (Model: NL-420S, Newlife® Medical Instrument, England) until a semi-solid residue (brownish black slurry) which weighed 4.38 g was obtained. The percentage yield was calculated and equivalent amount of the residue was separately reconstituted in distilled water to give the required doses of 100 and 200 mg/kg body weight used in the study.

#### Determination of Blood Glucose and Induction of Hyperglycaemia:

After eight hours of fast (without food, but water), blood glucose levels of the animals were determined before the administration of alloxan monohydrate by placing an aliquot (0.6 µL) of the blood on the test strip that had been inserted into the glucometer and reading the blood sugar level. Hyperglycaemia was then induced into animals following intraperitoneal administration of 1 ml corresponding to 150 mg/kg body weight of alloxan monohydrate solution (prepared in sterile physiological saline).

One hour after the administration of alloxan, the animals were equally given their pellet *ad libitum* and 5% dextrose solution to overcome the early hypoglycaemic phase<sup>39</sup>. The blood glucose was again determined after 24 h of alloxan administration. Rats with blood glucose level higher than 180.00 mg/dl were declared hyperglycaemic and included in the anti hyperglycaemic study<sup>40</sup>.

**Animal Grouping:** Fifteen hyperglycaemic and ten normal rats of both sexes (120 - 160 g) were completely randomized into five groups (A-E) of five rats each as follows:

**Group A:** Normal rats not induced with diabetes.

**Group B:** Normal rats that received aqueous leaf extract of *Newbouldia laevis*.

**Group C:** Alloxan-induced hyperglycaemic rats not treated, to serve as negative control.

**Group D:** Alloxan-induced hyperglycaemic rats treated with 100 mg/kg body weight of extract.

**Group E:** Alloxan-induced hyperglycaemic rats treated with 200 mg/kg body weight of extract.

Extract administration was done once daily for 14 days after which blood glucose levels were determined at interval of two days.

**Data Analysis:** Results were expressed as the mean of five determinations  $\pm$  SEM. Significant difference was determined by analysis of variance and Duncan's Multiple Range Test at 5% confidence level using SPSS 23.0 Software (Statistical Package for Social Sciences, Inc., Chicago, IL, USA).

**RESULTS:** Compared with the distilled water treated control animals after 24 h, administration of alloxan significantly ( $p < 0.05$ ) increased fasting blood glucose level from  $48.40 \pm 2.71$  to  $132.80 \pm 2.96$  mg/dl of animals in group C, from  $47.40 \pm 2.66$  to  $139.40 \pm 2.58$  mg/dl of animals in group D and from  $48.00 \pm 1.79$  to  $142.80 \pm 2.35$  mg/dl of animals in group E **Table 1**.

**TABLE 1: BLOOD GLUCOSE LEVEL BEFORE AND AFTER ALLOXAN INDUCTION FOR THE DIFFERENT GROUPS (AFTER 24 h)**

Group n = 5	Before Induction Mean $\pm$ SEM (mg/dl)	After Induction Mean $\pm$ SEM (mg/dl)
A	$547.80 \pm 2.26$	
B	$47.40 \pm 2.25$	
C	$48.40 \pm 2.71^a$	$132.80 \pm 2.96^b$
D	$47.40 \pm 2.66^a$	$139.40 \pm 2.58^b$
E	$48.00 \pm 1.79^a$	$142.80 \pm 2.35^b$

Data are mean of five determinations  $\pm$  SEM. Test values with superscript different from their respective group across the row are significantly different ( $p < 0.05$ )

**Day 2:** When group D was compared with the hyperglycaemic control group C, there was an increase in blood glucose but this was not statistically significant ( $p > 0.05$ ). Also, when group E was compared with the hyperglycaemic control group C, there was an increase in blood glucose level but this was not also statistically significant ( $p > 0.05$ ). Group E when compared with group D was higher but this was not statistically significant ( $p > 0.05$ ) **Table 2**.

**Day 4:** When group D was compared with the hyperglycaemic control group C, there was a decrease in blood glucose but this was not statistically significant ( $p > 0.05$ ). Also, when group E was compared with the hyperglycaemic control group C, there was a decrease in blood glucose level but this was not also statistically significant ( $p > 0.05$ ). Group D when compared with group E was higher but this was not statistically significant ( $p > 0.05$ ) **Table 2**.

**TABLE 2: COMPARISON BETWEEN THE VARIOUS DIABETIC GROUPS FOR DAY 2 AND DAY 4 AFTER INDUCTION**

Group n=5	Day 2 Mean $\pm$ SEM (mg/dl)	Day 4 Mean $\pm$ SEM (mg/dl)
C	$135.40 \pm 2.50^a$	$138.40 \pm 2.50^a$
D	$141.20 \pm 2.31^a$	$135.40 \pm 2.05^a$
E	$142.20 \pm 2.13^a$	$134.00 \pm 1.76^a$

Data are mean of five determinations  $\pm$  SEM. Test values with superscript different from their respective group down the column per day are significantly different ( $p < 0.05$ )

**Day 6:** When group D was compared with the diabetic control group C, there was a decrease in blood glucose which was statistically significant ( $p < 0.05$ ). Also, when group E was compared with the diabetic control group C, there was a decrease in blood glucose level which was also statistically significant ( $p < 0.05$ ). Group D when compared with group E was higher but this was statistically significant ( $p < 0.05$ ) **Table 3**.

**Day 8:** When group D was compared with the diabetic control group C, there was a decrease in blood glucose which was statistically significant ( $p < 0.05$ ). Also, when group E was compared with the diabetic control group C, there was a decrease in blood glucose level which was also statistically significant ( $p < 0.05$ ). Group D when compared with group E was higher but this was statistically significant ( $p < 0.05$ ) **Table 3**.

**TABLE 3: COMPARISON BETWEEN THE VARIOUS DIABETIC GROUPS FOR DAY 6 AND DAY 8 AFTER INDUCTION**

Group n=5	Day 6 Mean $\pm$ SEM (mg/dl)	Day 8 Mean $\pm$ SEM (mg/dl)
C	$138.20 \pm 2.44^a$	$139.00 \pm 2.21^a$
D	$130.00 \pm 1.76^b$	$121.80 \pm 1.07^b$
E	$120.80 \pm 1.11^c$	$111.20 \pm 1.07^c$

Data are mean of five determinations  $\pm$  SEM. Test values with superscript different from their respective group down the column per day are significantly different ( $p < 0.05$ )

**Day 10:** When group D was compared with the diabetic control group C, there was a decrease in blood glucose which was statistically significant ( $p < 0.05$ ). Also, when group E was compared with the diabetic control group C, there was a decrease in blood glucose level which was also statistically significant ( $p < 0.05$ ). Group D when compared with group E was higher but this was statistically significant ( $p < 0.05$ ) **Table 4**.

**Day 12:** When group D was compared with the diabetic control group C, there was a decrease in blood glucose which was statistically significant ( $p < 0.05$ ). Also, when group E was compared with the diabetic control group C, there was a decrease in blood glucose level which was also statistically significant ( $p < 0.05$ ). Group D when compared with group E was higher but this was statistically significant ( $p < 0.05$ ) **Table 4**.

**Day 14:** When group D was compared with the diabetic control group C, there was a decrease in blood glucose which was statistically significant ( $p < 0.05$ ). Also, when group E was compared with the diabetic control group C, there was a decrease in blood glucose level which was also statistically significant ( $p < 0.05$ ) **Table 4**.

**TABLE 4: COMPARISON BETWEEN THE VARIOUS DIABETIC GROUPS FOR DAY 10, 12 AND DAY 14 AFTER INDUCTION**

Group n= 5	Day 10 Mean $\pm$ SEM (mg/dl)	Day 12 Mean $\pm$ SEM (mg/dl)	Day 14 Mean $\pm$ SEM (mg/dl)
C	139.00 $\pm$ 2.07 <sup>a</sup>	140.00 $\pm$ 1.95 <sup>a</sup>	139.60 $\pm$ 2.06 <sup>a</sup>
D	109.60 $\pm$ 0.81 <sup>b</sup>	94.20 $\pm$ 1.24 <sup>b</sup>	84.60 $\pm$ 1.29 <sup>b</sup>
E	95.00 $\pm$ 1.84 <sup>c</sup>	84.40 $\pm$ 0.81 <sup>c</sup>	70.60 $\pm$ 1.36 <sup>c</sup>

Data are mean of five determinations  $\pm$  SEM. Test values with superscript different from their respective group down the column per day are significantly different ( $p < 0.05$ )

**DISCUSSION:** The present study revealed a dose specific pharmacologic activity of the aqueous leaf extract of *N. laevis* at 100 and 200 mg/kg body weight. Alloxan monohydrate is a hydrophilic and unstable compound of glucose analogues that specifically accumulate in pancreatic  $\beta$ -cells via the Glucose Transporter 2<sup>41</sup> to induce hyperglycaemia (type I diabetes)<sup>9, 42</sup>. The cytotoxic activity of alloxan monohydrate involves oxidation of essential sulphhydryl (-SH) group, inhibition of glucokinase enzymes, generation of free radicals and disturbance of intracellular calcium homeostasis<sup>42</sup>.

The presence of intracellular thiols, especially glutathione, generates reactive oxygen species (ROS) in a cyclic redox reaction with its reduction product, dialuric acid<sup>43</sup>. Autoxidation of dialuric acid produces superoxide radicals, hydrogen peroxide and, in a final iron-catalysed reaction step, hydroxyl radicals<sup>44</sup>. These free radicals are ultimately responsible for the death of the beta cells, which have a particularly low antioxidant

defence capacity, and the ensuing state of insulin-dependent 'alloxan-induced hyperglycaemia'<sup>45</sup>. This is the fundamental mechanism underlying alloxan-induced hyperglycemia in the distilled water treated hyperglycaemic rats after 24 h of alloxan induction. The increase in blood glucose level by alloxan in the distilled water treated hyperglycaemic animals may also be attributed to over-production (excessive hepatic glycogenolysis and gluconeogenesis) and decreased utilization of glucose by the tissues<sup>6</sup>.

The non-significant increase in blood glucose level after day 2 by the extract at 100 and 200 mg/kg body weight (group D and E) when compared with the animals in group C imply that the extract may not affect glucose metabolism. This might not be unconnected with the 5% dextrose solution administered upon hyperglycaemia to overcome the early hypoglycaemic phase<sup>39</sup>. The non-significant decrease in blood glucose level by the extract at 100 and 200 mg/kg body weight (group D and E) when compared with group C, on day 4, may signal an onset of restoration of the damaged insulin producing pancreatic  $\beta$ -cells of the animals<sup>46, 47</sup>. The reduction in elevated blood glucose level by the extract of animals in group D and E when compared with those in group C on days 6, 8, 10, 12 and 14 may be due to the antihyperglycaemic effect of the extract which could have acted by stimulating glucose utilization by peripheral tissues or increasing insulin production by the pancreas from regenerated  $\beta$ -cells<sup>48, 49, 50</sup>. Overall, available evidence from the present study suggests that the aqueous leaf extract of *N. laevis* attenuated alloxan-induced hyperglycaemia in Wistar rats.

**CONCLUSION:** Experimental evidence obtained from this study indicate that the aqueous leaf extract of *N. laevis* at 100 and 200 mg/kg body weight facilitated pancreatic insulin secretion and glucose uptake in alloxan-induced hyperglycaemic rats.

**ACKNOWLEDGEMENT:** The authors of this work wish to acknowledge the technical assistance of the chief technologist and other laboratory assistants of the Department of Physiology, Faculty of Basic Medical Sciences, Nnamdi Azikiwe University, Nnewi Campus, Anambra State, Nigeria, towards ensuring that this research study

was completed in a good record time. Indeed, we are sincerely grateful.

**COMPETING INTERESTS:** Authors have declared that no competing interests exist.

**RECOMMENDATION:** This investigation suggests the presence of biologically active components (principles) in the 100 and 200 mg/kg body weight of *N. laevis* leaf which may be worthy of further research and elucidation.

## REFERENCES:

1. Umpierrez G and Pasquel F: Management of Inpatient Hyperglycemia and Diabetes in Older Adults. *Diabetes Care* 2017; 40(4):509-17.
2. Francine U, Jeanette U and Pierre RJ: Assessment of antibacterial activity of Neem plant (*Azadirachta indica*) on *Staphylococcus aureus* and *Escherichia coli*; *JMPS* 2015; 3(4): 85-91.
3. Jerobin J, Makwana P, Sureshkumar RS, Sundaramoorthy R, Mukherjee A and Chandrasekaran N: Antibacterial activity of Neem nanoemulsion and its toxicity assessment on human lymphocytes in-vitro. *Int J Nanomedicine* 2015; 10(S1): 77-86.
4. Salada JT, Balala LM and Vasquez EA: Phytochemical and antibacterial studies of *Lantana camara* L. leaf fraction and essential oil. *IJSRP* 2015; 5: 3.
5. Eze ED, Tanko Y, Tende JA and Ehinomhen UA: Effects of lycopene on liver markers and glucokinase activity in experimentally induced diabetes mellitus rat model. *Journal of Basic and Applied Research* 2016; 2(3): 353-362.
6. Geijselaers S, Sep S, Claessens D, Schram M, van-Boxtel M and Henry R: The Role of Hyperglycemia, Insulin Resistance, and Blood Pressure in Diabetes-Associated Differences in Cognitive Performance. *The Maastricht Study. Diabetes Care* 2017; 40(11): 1537-47.
7. Madhav SNV, Bhattacharya S, Uniyal SN and Nautiyal A: A detailed review on diabetes mellitus and its treatment in allopathic and alternative systems. *Pharmanest. An International Journal of Advances in Pharmaceutical Sciences* 2013; 4(1): 16-43.
8. Kavitha R: Effect of ethanolic extracts of leaf and fruit of *Trichosanthes dioica* and leaf of *Clitoria ternatea* on serum lipids in streptozotocin-induced diabetic rats. *Int J Pharm Bio Sci.* 2015; 6(4): 430-439.
9. Eze ED, Mohammed A, Tanko Y, Abubakar A and Rabiou KM: Hypoglycaemic effect of lycopene in streptozotocin-induced diabetic Wistar rats. *British Journal of Medicine and Medical Research* 2015; 7(9): 762-770.
10. Davis S: Oral hypoglycaemic drugs for the treatment of type 2 diabetes mellitus. *South African Pharmaceutical Journal* 2012; 79(3): 22-24.
11. Bathaie SZ, Mokarizade N and Shirali S: An overview of the mechanisms of plant ingredients in the treatment of diabetes mellitus. *Journal of Medicinal Plants* 2012; 11(44): 1-24.
12. Agrawal MK, Varma A and Goyal S: antibacterial screening of extracts of the leaves of *Lantana camara*. *Indian. J. L. Sci.* 2012; 1(2): 97-99.
13. Ojiako KA, Chikezie PC and Ogbuji AC: Blood glucose level and lipid profile of alloxan-induced hyperglycemic rats treated with single and combinatorial herbal formulations. *Journal of traditional and complementary Medicine* 2016; 6(2): 184-192.
14. Rachmat II, Yuslianti ER, Permatasari GF and Koswara T: Antihyperglycemic Effect of Rambutan Honey in Alloxan-induced Diabetic Wistar Rats. *Journal of Pharmacology and Toxicology* 2017; 12: 42-49.
15. Noor A, Bansal VS and Vijayalakshmi MA: Current update on anti-diabetic biomolecules from key traditional indian medicinal plants. *Current Science*, 2013; 104(6): 721-727.
16. Behera B and Yadav D: Current researches on plants having antidiabetic potential-an overview research and reviews: *Journal of Botanical Sciences* 2013; 2(2): 4-17.
17. Okafor, JC: Horticulturally promising indigenous wild plant species of the Nigerian forest zone acts. *Horticulture* 1983; 123: 165-177.
18. Edeoga HO, Okwu DE and Mbaebie BO: Phytochemical constituents of some Nigerian medicinal plants. *African Journal of Biotechnology* 2005; 4(7): 685-688.
19. Dixit PK and Mittal S: A comprehensive review on anti-diabetic agents of herbal origin. *International Journal of Pharmacy and Pharmaceutical Sciences* 2013; 5(2): 29-32.
20. Guariguata L, Whiting D, Hambleton I, Beagley J, Linnenkamp U and Shaw J: Global estimates of diabetes prevalence for 2013 and projections for 2035. *Diabetes research and clinical practice* 2014; 103(2): 137-149.
21. American Diabetes Association: Diagnosis and classification of diabetes mellitus. *Diabetes Care* 2007; 98(1): 37-43.
22. Garaniya N and Bapodra A: Ethno botanical and Phytopharmacological potential of *Abrus precatorius* L.: A review. *Asian Pac J Trop Biomed* 2014; 4(1): S27-S34.
23. Pathak K and Das RJ: Herbal Medicine- A rational approach in health care system. *International Journal of Herbal Medicine* 2013; 1(3): 86-89.
24. Gupta PD and De A: Diabetes Mellitus and its Herbal Treatment. *International Journal of Research in Pharmaceutical and Biomedical Sciences* 2012; 3(2): 706-721.
25. Gbile ZO: Ethnobotany, Taxonomy and Conservation of Medicinal Plants: In: *The state of Medicinal Plant Research in Nigeria*. Sofowora, A. (Ed) University of Ibadan, Ibadan, Nigeria, 1986.
26. Ogunlana OE and Ogunlana OO: *In-vitro* assessment of antioxidant activity of *Newbouldia leavis*. *Journal of Medicinal Plants Research* 2008; 2(8): 176-179.
27. Iwu MM: Traditional Igbo Medicine. Report of a Project Sponsored by the Institute of African Studies, University of Nigeria, Nsukka 1983.
28. Burkill HM: The useful plants of West Tropical Africa. Royal Botanical Garden Kew 1984; 2: 458-463.
29. Gill LS: *Ethnomedical Uses of Plants in Nigeria*. Ethnobotany 1992, Uniben Press, 276 pages. ISBN 9782027200, 9789782027207.
30. Amos S, Binda L, Vongtau H, Chindo B, Abbah J, Sambo N, Odin EM, Okwute SR, Arah P, Wambebe C and Gamaniel K: Sedative effects of the methanolic leaf extract of *Newbouldia leavis* in mice and rats. *Bollettino Chimico Farmaceutico* 2002; 141(6): 471-475.
31. Owolabi OJ, Amaechina FC and Okoro M: Effect of ethanol leaf extract of *Newbouldia leavis* on blood glucose levels of diabetic rats. *Tropical Journal of Pharmaceutical Research* 2011; 10(3): 249-254.
32. Osigwe CC, Akah PA and Nworu CS: Biochemical and haematological effects of the leaf extract of *Newbouldia*

- laevis* in alloxan-induced diabetic rats. Journal of Biosciences and Medicine 2017; 5: 18-36.
33. Bosha JA, Adenkola AY and Asuzu IU: Erythrocyte stability, membrane protective and haematological activities of *Newbouldia laevis* in alloxan-induced diabetic rats. Sokoto Journal of Veterinary Sciences 2016; 14(1): 16-25.
34. Egba SI, Sunday GI and Anaduaka EG: The effect of oral administration of aqueous extract of *Newbouldia laevis* leaves on fertility hormones of male albino rats. IOSR Journal of Pharmacy and Biological Sciences (IOSR-JPBS) 2014; 9(3): 61-64.
35. Anaduaka EG, Ogugua VN, Agu CV and Okonkwo CC: Ethanol extract of *Newbouldia laevis* stem and leaves modulate serum liver marker enzyme and antioxidant enzyme activities in diabetic rats. African Journal of Biotechnology 2014; 13(22): 2265-2272.
36. Omonkhehin JO, Fabian CA and Mercy O: Effect of Ethanol Leaf Extract of *Newbouldia laevis* on Blood Glucose Levels of Diabetic Rats. Tropical Journal of Pharmaceutical Research 2011; 10 (3): 249-254.
37. Ajah O, Unegbu CC, Uzomba NI, Nnaoma IE and Chinyere IG: Hypoglycemic activity of aqueous leave extract of *Newbouldia laevis* on alloxan induced diabetes in male albino rats. European Journal of Basic and Applied Sciences 2016, 3(2): 15-18.
38. Osigwe CC, Akah PA, Nworu CS, Okoye TC and Tchime MK: Antihyperglycemic studies on the leaf extract and active fractions of *Newbouldia laevis* (Bignoniaceae). Pharmacology & Pharmacy 2015; 6: 518-532.
39. Hassanpour SH, Dehghani MA, Karami SZ and Dehghani F: Role of mitochondria in diabetes and its complications. IJPSR 2018; 9(6): 2185-2189.
40. Kim J, Choi J, Lee M, Kang K, Paik M, Jo S, Jung U, Park H and Yee S: Immunomodulatory and antidiabetic effects of a new herbal preparation (HemoHIM) on streptozotocin-induced diabetic mice. Evidence-Based Complementary and Alternative Medicine 2014; Volume 2014, Article ID 461685, 8 pages.
41. Boggula N, Chettupalli AN, Reddy S, Reddy N and Bakshi V: Anti diabetic effect of *Alstonia scholaris* Linn. bark in Alloxan induced diabetic rats. Journal of Global Trends in Pharmaceutical Sciences 2017; 8(1): 3590-3598.
42. Hosseini S, Gorjian M, Rasouli L and Shirali S: A comparison between the effect of green tea and kombucha prepared from green tea on the weight of diabetic rats. Biosciences Biotechnology Res. Asia 2015; 12: 141-146.
43. Pandir D, Unal B and Bas H: Lycopene protects the diabetic rat kidney against oxidative stress-mediated oxidative damage induced by furan. Brazilian Archives of Biology and Technology 2016; 59: 1-12.
44. Shahana S and Nikalje APG: Effect of *Trichosanthes dioica* aqueous fruit extract in diabetes and diabetic complications. International Journal of Pharmaceutical Science and Research 2018; 9(6): 2540-2544.
45. Parashar G, Sutar N, and Sanap S: Antibacterial activity of mixture of leaf extracts of Neem (*Azadirachta indica* Linn.) and Tantani (*Lantana camara*). International Journal of Pharmaceutical Science and Research 2018; 9(6): 2545-2549.
46. Boggula N, Elsani MM and Kaveti VS: Pharmacognostic, Phytochemical analysis and anti diabetic activity of dried leaves of *Abrus precatorius* – an *in-vivo* approach. International Journal of Pharmaceutical Sciences and Drug Research 2018; 10(3): 118-124.
47. Santulli G, Pagano G, Sardu C, Xie W, Reiken S, D'Ascia SL, Cannone M, Marziliano N, Trimarco B, Guise TA, Lacampagne A and Marks AR: Calcium release channel RyR2 regulates insulin release and glucose homeostasis. Journal of Clinical Investigation. 2015; 125(5): 1968-78.
48. Ebrahimi E, Bahramzadeh S, Hashemitabar M, Mohammadzadeh G, Shirali S and Jodat J: Effect of Hydroalcoholic Leaf Extract of *Citrullus colocynthis* on induction of insulin secretion from isolated rat islet of Langerhans. Asian Journal of Tropical Disease 2016; 6, 638-41.
49. Gupta S, Toppo KI, Karkun D and Kumar A: Study of antibacterial activity of *Lantana indica* against some human pathogens and its phytochemicals. EJPMR 2016; 3(2): 301-308.
50. Mahdizadeh R, Sharifat M, Shirali S and Tarrah A: Investigation of changes in levels of serum elements, lipid profile and advanced glycation end product in patients with type 2 diabetes. International Journal of Biology, Pharmacy and Allied Sciences (IJBPAS) 2015; 4(7): 244-261.

#### How to cite this article:

Igbokwe UV, Eze ED, Adams MD, Atsukwei D and Ikechukwu M: *Newbouldia laevis* leaf facilitates insulin secretion, glucose uptake and pancreatic function in alloxan-induced hyperglycaemia in wistar rats. Int J Pharm Sci & Res 2018; 9(12): 5079-85. doi: 10.13040/IJPSR.0975-8232.9(12).5079-85.

All © 2013 are reserved by International Journal of Pharmaceutical Sciences and Research. This Journal licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License.

This article can be downloaded to **ANDROID OS** based mobile. Scan QR Code using Code/Bar Scanner from your mobile. (Scanners are available on Google Playstore)